Rein Therapeutics Inc (NASDAQ: RNTX) is a clinical-stage biopharmaceutical company focused on developing drug candidates for serious and life-threatening diseases. It has not generated any revenue from product sales as of the 10-K filed March 26, 2026, and does not expect product revenue in the foreseeable future. The company funds operations through equity offerings and warrant exercises rather than commercial sales. In May 2024, an underwritten follow-on public offering raised $17.7 million in net proceeds. In April 2025, warrant exercises and exchanges generated an additional $4.6 million in net proceeds. Operating expenses consist solely of research and development costs, general and administrative expenses, and restructuring costs. The lead clinical asset is LTI-01, a plasminogen activator evaluated in a Phase 2a trial for infected, non-draining pleural effusions across 36 U.S. centers. Leadership as of March 26, 2026 includes Brian Windsor, Ph.D. as President and CEO, and Timothy M. Cunningham as Interim CFO.

Revenue model

No product revenue. The company finances operations through public equity offerings and warrant transactions. Net proceeds from a May 2024 follow-on offering totaled $17.7 million. Warrant exercises and exchanges in April 2025 generated approximately $4.6 million in net proceeds.

Products and services

LTI-01, a plasminogen activator evaluated in a Phase 2a randomized, double-blind, placebo-controlled clinical trial for infected, non-draining pleural effusions. The trial enrolled 40 patients across 36 U.S. centers and tested three dose levels: 400,000, 800,000, and 1.2 million units versus placebo. No products are approved or commercially available as of the filing date.

Customers and end markets

No commercial customers. End market targets are patients with serious pulmonary and pleural conditions. Potential future customers would include hospitals and health systems subject to bidding procedures and pharmaceutical pricing regulations.

Value-chain role

Early-stage drug developer. The company conducts preclinical studies and clinical trials, and sources platform materials and product candidates partially from external manufacturers including suppliers in China. It has no commercial manufacturing, distribution, or sales infrastructure.

Geographic exposure

Primary operations in the United States. Clinical trials conducted domestically. The company may seek to conduct clinical trials in the European Economic Area and is subject to GDPR considerations. Some manufacturing inputs sourced from China.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: APPLIED GENETIC TECHNOLOGIES CORP Inhibitor Therapeutics Inc Viskase Holdings Inc Indaptus Therapeutics Inc Metacrine, Inc. NanoViricides, Inc CapForce Inc. VivoSim Labs Inc